GW Pharmaceuticals plc’s Stock Is Buy After Today’s Huge Increase

 GW Pharmaceuticals plc's Stock Is Buy After Today's Huge Increase

The stock of GW Pharmaceuticals plc (LON:GWP) is a huge mover today! The stock decreased 0.04% or GBX 0.34 on November 28, hitting GBX 799.66. About 1.72M shares traded hands or 161.79% up from the average. GW Pharmaceuticals plc (LON:GWP) has risen 69.94% since April 27, 2016 and is uptrending. It has outperformed by 63.93% the S&P500.
The move comes after 9 months positive chart setup for the GBX 2.42 billion company. It was reported on Nov, 28 by Barchart.com. We have GBX 855.64 PT which if reached, will make LON:GWP worth GBX 169.40 million more.

More notable recent GW Pharmaceuticals plc (LON:GWP) news were published by: Fool.com which released: “Why You Should (and Shouldn’t) Buy GW Pharmaceuticals Plc” on August 26, 2016, also Reuters.com with their article: “Exclusive: GW Pharmaceuticals hires investment bank following approaches -…” published on September 07, 2016, Bloomberg.com published: “GW Pharma Plans to Cancel U.K. Listing in Favor of Nasdaq” on October 19, 2016. More interesting news about GW Pharmaceuticals plc (LON:GWP) were released by: Fool.com and their article: “GW Pharmaceuticals in 5 Charts” published on September 22, 2016 as well as Investorplace.com‘s news article titled: “GW Pharmaceuticals (GWPH) Stock Landed a 1-2 Ballot Punch” with publication date: November 11, 2016.

GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The company has a market cap of 2.42 billion GBP. The Firm develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies. It currently has negative earnings. The Firm operates through three divisions: Commercial, Sativex Research and Development , and Pipeline Research and Development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment